Mechanism of Action
SNS01 is a first-in-class antibody with novel molecular target (CDx) which inhibits the tumor growth and cytokines secrets by tumor cells. CDx can also regulate PD-L1 protein expression and be combined with immune checkpoint inhibitors to maximize the treatment response by activating the suppressed T cells in patients.
SNS01 is under pre-clinical development.
1st target indication will be NSCLC with market forecast to be US$6.39 billion in 2025 according to Allied Market Research.